Keywords: roche, pay, up, 555m, rights, actelion, phase
Roche to pay up to $555M for 50% rights to Actelion's Phase I S1P1 immunomodulator
Article | 24 July 2006
Swiss drugmakers Roche and Actelion have entered into an exclusive worldwide collaboration to jointly develop and commercialize the latter's selective ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
